Citadel Advisors’s Harvard Bioscience HBIO Stock Holding History

Citadel Advisors’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,150	Closed	-$5.1K	–	13314
2025 Q2	$5.1K	Buy	1,150 +950	+475%	+$3.97K	﹤0.01%	12231
2025 Q1	$1.13K	Sell	200 -1,300	-87%	-$16.6K	﹤0.01%	14163
2024 Q4	$31.6K	Buy	1,500 +1,290	+614%	+$29.6K	﹤0.01%	12818
2024 Q3	$5.65K	Buy	210 +90	+75%	+$2.65K	﹤0.01%	13470
2024 Q2	$3.42K	Sell	120 -100	-45%	-$3.51K	﹤0.01%	13598
2024 Q1	$9.33K	Buy	+220	New	+$9.89K	﹤0.01%	13509
2023 Q4	–	Sell	-140	Closed	-$6.02K	–	14684
2023 Q3	$6.02K	Buy	140 +120	+600%	+$5.54K	﹤0.01%	13352
2023 Q2	$1.1K	Sell	20 -20	-50%	-$1.1K	﹤0.01%	13988
2023 Q1	$1.68K	Buy	+40	New	+$1.19K	﹤0.01%	14257

Other funds holding HBIO

WCM

Weber Capital Management San Francisco, California $118M AUM

MIM

Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

CCM

Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's HBIO Position: Q2 2026 in Review

Citadel Advisors opened a new position in Harvard Bioscience (HBIO) in Q2 2026: 13,251 shares worth $81.5K. The stake represents ﹤0.01% of the portfolio and ranks #12835 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in HBIO as recently as Q4 2025.

Citadel Advisors first reported a position in HBIO in Q2 2013 and has held it in 28 quarters since. The position peaked at $537K in Q2 2022. 37 funds tracked by Wall St. Rank hold HBIO as of Q2 2026.

Citadel Advisors held 13,251 shares of Harvard Bioscience worth $81.5K as of Q2 2026.
Harvard Bioscience was a new Citadel Advisors position in Q2 2026.
Harvard Bioscience made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12835 holding.
Citadel Advisors first reported a position in Harvard Bioscience in Q2 2013 and has held it in 28 quarters since.
Citadel Advisors's Harvard Bioscience position peaked at $537K in Q2 2022.
37 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.